Once-monthly risedronic acid is noninferior to daily risedronic acid in the treatment of postmenopausal osteoporosis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1615, 2007-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alendronic acid superior to risedronic acid in osteoporosis

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Alendronic acid superior to risedronic acid for osteoporosis

Inpharma, Vol. 1, Iss. 1365, 2002-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Risedronic acid + HRT increases postmenopausal BMD

Inpharma, Vol. 1, Iss. 1295, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Risedronic acid: Hypocalcaemia: case report

Reactions Weekly, Vol. 1, Iss. 1129, 2006-01 ,pp. : 18-19

Adis International

Access to resources Recommend Favorite

Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis: Results of FACTS1 1 Fosamax Actonel Comparison Trials. -International

By Reid David M.

Clinical Drug Investigation, Vol. 26, Iss. 2, 2006-01 ,pp. : 63-74

Adis International

Access to resources Recommend Favorite